Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.52 |
| ▸ | F2 | P00734 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | TNKS | O95271 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1570725 | 1.00 | CYP3A4 (0.55) | CYP3A4CYP2C9PKMCYP2C19ALDH1A1 | |
| SCHEMBL3320815 | 1.00 | CYP3A4 (0.55) | CYP3A4CYP2C9PKMCYP2C19ALDH1A1 | |
| SCHEMBL27394992 | 0.85 | CYP3A4 (0.72) | CYP3A4CYP2C9PKMCYP2C19ALDH1A1 | |
| SCHEMBL8096850 | 0.85 | CYP3A4 (0.72) | CYP3A4CYP2C9PKMCYP2C19ALDH1A1 | |
| SCHEMBL8102978 | 0.76 | TSHR (0.61) | CYP3A4CYP2C9PKMCYP2C19ALDH1A1 | |
| SCHEMBL3321589 | 0.76 | NPSR1 (0.52) | CYP2C9PKMCYP2C19ALDH1A1POLB | |
| SCHEMBL8104234 | 0.76 | POLB (0.65) | CYP3A4CYP2C9PKMCYP2C19POLB | |
| SCHEMBL1865687 | 0.73 | PKM (0.55) | PKMALDH1A1NPC1POLBGAA | |
| SCHEMBL1570482 | 0.73 | PKM (0.55) | PKMALDH1A1NPC1POLBGAA | |
| SCHEMBL3321686 | 0.73 | PKM (0.55) | PKMALDH1A1NPC1POLBGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2307385-A1 | 2 -ARYLAMINOQUINAZOLINES FOR TREATING PROLIFERATIVE DISEASES | Novartis AG (CH) | 2011-04-13 | — | — | EP | disclosed |
| US-20100216767-A1 | QUINAZOLINES FOR PDK1 INHIBITION | AIKAWA MINA | 2010-08-26 | — | — | US | disclosed |
| US-20100121052-A1 | Novel compounds for treating proliferative diseases | JAIN RAMA | 2010-05-13 | — | — | US | disclosed |
| WO-2009153313-A1 | 2 -ARYLAMINOQUINAZOLINES FOR TREATING PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2009-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216767-A1 | QUINAZOLINES FOR PDK1 INHIBITION | PDK1, PDK2, PDK3 | CYP3A4 4369/4885CYP2C9 4755/4885PKM 51/4885 |
| US-20100121052-A1 | Novel compounds for treating proliferative diseases | PDK1, PDK2, PDK3 | CYP3A4 4774/4885CYP2C9 4866/4885PKM 91/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.